

The Memorial Sloan Kettering Tow Center for Developmental Oncology presents the

2024

# Robert Steel Symposium in Developmental Oncology

APRIL 29—30 • NEW YORK, NY

Memorial Sloan Kettering Cancer Center  
Zuckerman Research Center



Memorial Sloan Kettering  
Cancer Center

# Overview

**This Symposium brings together outstanding scientists from across the country to discuss the latest discoveries into the molecular mechanisms of cancers in children and young adults and the development of new approaches for their definitive therapy and control.**

The program will provide a unique opportunity to discuss genetic and epigenetic regulation of developmental processes, the molecular characterization of childhood cancers, and the identification of novel therapeutic strategies. There are **many unanswered questions that need to be addressed** for childhood and young adult cancers:

- What causes cancer in children and young adults without inheritance of cancer-predisposing mutations or exposure to environmental mutagens?
- How do predisposing alleles and exposures contribute to cancer development?
- What developmental processes are dysregulated to cause mutations and cell transformation in otherwise healthy tissues?
- How do mutations in developmental pathways involving transcription factors and epigenetic signaling cause cancer?
- How do we design effective therapeutics to block, activate, and modulate protein interactions that control transcription factors and other developmental regulators?
- How do we identify targets for immune therapy in developmental tumors that have relatively few mutations?

This two-day live, in-person Symposium provides an intimate and exciting setting to share new advances for these questions. It will also allow an **opportunity for established and young investigators to discuss new questions and interdisciplinary approaches of relevance** to young-onset cancer biology.

## TARGET AUDIENCE

The target audience for this Symposium includes scientists, physicians, APPs, nurses, and other healthcare providers interested in learning the latest advances in our understanding of the biology and therapy of childhood cancers. **We invite students and trainees to attend this Symposium on a complimentary basis as well as registrants that reside and practice in low and lower-middle income countries.**

## LOCATION

This Symposium is set to be an **exclusively in-person event** on the campus of Memorial Sloan Kettering; a virtual option is not available. Ample time will be provided for networking and professional collaboration.

Mortimer B. Zuckerman Research Center  
1417 East 68<sup>th</sup> Street





# Schedule

**MONDAY, APRIL 29, 2024**

ZUCKERMAN RESEARCH CENTER (ZRC) AUDITORIUM

8:00 AM	Registration and Breakfast ZRC LOBBY
8:50 AM	<b>Welcome and Introduction</b> Andrew Kung, MD, PhD
9:00 AM	 <b>Rewiring Cancer Drivers to Activate Apoptosis with Chemically Induced Proximity</b> Gerald Crabtree, MD Stanford University
9:40 AM	 <b>Formaldehyde — An Endogenous Mutagen That Drives Clonal Blood Production</b> KJ Patel, FRS, FMedSci University of Oxford
10:20 AM	<b>YBX1 as a Regulator of Medulloblastoma Initiation and Progression</b> Myron K. Evans II, PhD Seattle Children's Research Institute
10:40 AM	<b>Epigenetic Effects of Histone 3.3 Mutations in Neural and Mesenchymal Development</b> Alva Annett, MSc McGill University
11:00 AM	<b>When Things Go off TRK: The Intersection of Neuroscience and Oncology</b> Siobhan S. Pattwell, PhD Seattle Children's Research Institute
11:20 AM	Break
11:40 AM	<b>Modeling Kiaa1549-Braf Tandem Duplication</b> Ylenia Cendon Florez, PhD Memorial Sloan Kettering Cancer Center
12:00 PM	<b>Polycomb Repressor Complex-Mediated Regulation of HOXA7 Signaling is Essential for Glioma Progression</b> Sheila Alcantara Llaguno, MD, PhD Memorial Sloan Kettering Cancer Center
12:20 PM	 <b>Big Data for Functional Precision Medicine in Myeloid Malignancies</b> Jeffrey Tyner PhD OHSU Knight Cancer Institute

1:00 PM	Lunch ZRC LOBBY
1:40 PM	<p><b>Second Somatic NFI Mutations Pervade the Normal Tissues of the Nervous System in Neurofibromatosis Type 1</b></p> <p><b>Thomas R. W. Oliver, MD</b> Addenbrooke's Hospital</p>
2:00 PM	<p><b>Enhancing the Persistence and Anti-tumor Efficacy of CAR-T and CAR-NK cells for Pediatric Malignancies through Genetic Disruption of Death Receptors</b></p> <p><b>Tal Cohen, MD</b> Memorial Sloan Kettering Cancer Center</p>
2:20 PM	<p><b>NUP98-fusion Proteins and KMT2A-MENIN Antagonize PRC1.1 to Drive Gene Expression in AML</b></p> <p><b>Emily B. Heikamp, MD, PhD, MSc</b> Dana-Farber Cancer Institute Boston Children's Hospital Cancer and Blood Disorders Center</p>
2:40 PM	<p><b>Proteolytic Control of Oncogenic Gene Expression in Acute Myeloid Leukemia</b></p> <p><b>Masahiro Uni, MD, PhD</b> Memorial Sloan Kettering Cancer Center</p>
3:00 PM	<p><b>Quiescent and Stem Like Signature with NUP98-NSD1 Fusion Driven Childhood Leukemia</b></p> <p><b>Elvin Wagenblast, PhD</b> Icahn School of Medicine at Mount Sinai</p>
3:20 PM	<p><b>Pediatric BPDCN Associated MYB Fusions Regulate Cell Cycle Genes and Initiate Leukemia In Vivo</b></p> <p><b>Christopher Booth, PhD</b> Dana-Farber Cancer Institute</p>
3:40 PM	Break
4:00 PM	 <p><b>Transcriptional Condensates in Cell Fate Control and Cancer</b></p> <p><b>Liling Wan, PhD</b> UPenn Perelman School of Medicine</p>
4:40 PM	 <p><b>Interplay Between Epigenetic and Genetic Cancer Drivers</b></p> <p><b>Bradley Bernstein, MD, PhD</b> Dana-Farber Cancer Institute</p>
5:20 PM	<p><b>Closing Remarks and Adjournment</b></p> <p>Agata Smogorzewska, MD, PhD</p>

## NETWORKING RECEPTION AND DINNER

Upstairs at The Kimberly Hotel  
6:00—9:00 PM  
145 East 50th Street

**TUESDAY, APRIL 30, 2024**

ZUCKERMAN RESEARCH CENTER (ZRC) AUDITORIUM


8:45 AM Breakfast  
ZRC LOBBY

9:25 AM **Welcome and Introduction**  
Alex Kentsis, MD, PhD

9:30 AM  **Pediatric Fusion Oncogene Sarcomas:  
New Insights From Zebrafish Genetic Models**  
**James Amatruda, MD, PhD**  
Children's Hospital Los Angeles

10:10 AM **ETV6 Dependency in Ewing Sarcoma Through  
Antagonism of Ews-FLI1-Mediated Enhancer Activation**  
**Yuan Gao, PhD**  
Cold Spring Harbor Laboratory

10:30 AM **Epigenetic Control of Neuroblastoma Differentiation  
Through Inhibiting KAT6A/B Activity**  
**Nina Weichert-Leahey, MD**  
Harvard Medical School, Dana-Farber Cancer Institute

10:50 AM  **MYCN Overexpression Biases Human  
Sympatho-Adrenergic Development Towards  
Progenitor Cells Causing Neuroblastoma-Like  
Tumor Xenografts**  
**Stephen Roberts, MD**  
Oregon Health and Science University

11:30 AM Break

11:50 AM **Developmental Deconvolution for Classification  
of Cancer Origin**  
**Enrico Moiso, PhD, MSc**  
Memorial Sloan Kettering Cancer Center

12:10 PM  **Medulloblastoma Arises Secondary to Failure  
of Differentiation of the Homo Sapiens  
Rhombic Lip**  
**Michael Taylor, MD, PhD**  
Texas Children's Hospital

12:50 PM **Closing Remarks and Adjournment**  
Alex Kentsis, MD, PhD

1:00 PM Lunch  
ZRC LOBBY

**#MSKDEVONC #MSKKIDS**

**[msk.org/DevelopmentalOncology](https://msk.org/DevelopmentalOncology)**





We invite attendees to join the symposium faculty for a **complimentary networking reception and dinner.**

**Monday, April 29, 2024**  
**6:00—9:00 PM**

**Upstairs at The Kimberly Hotel**  
145 East 50<sup>th</sup> Street  
[upstairsnyc.com](http://upstairsnyc.com)

Upstairs at The Kimberly Hotel is a one-of-a-kind rooftop experience in the heart of New York City, focused on refined service in a relaxed luxurious setting. RSVP to the reception is required during Symposium registration.

This Symposium is presented by the **MSK Tow Center for Developmental Oncology**, which unites scientists across MSK to develop fundamental insights into the molecular mechanisms of cancers in children and young adults, and to devise new approaches for definitive therapy and control.

## Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **10.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ABP MOC RECOGNITION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 10.25 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit





## Symposium Organizers



**Alex Kentsis, MD, PhD**

Associate Member  
Molecular Pharmacology Program  
Director, Tow Center for Developmental Oncology  
Memorial Sloan Kettering Cancer Center



**Andrew Kung, MD, PhD**

Chair, Department of Pediatrics  
Memorial Sloan Kettering Cancer Center



**Agata Smogorzewska, MD, PhD**

Professor  
The Rockefeller University

## Peer Reviewer



**Makiko Yamada, MD, PhD**

Senior Research Scientist  
Memorial Sloan Kettering Cancer Center

### RELEVANT FINANCIAL RELATIONSHIPS

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

# Speakers

**SHEILA ALCANTARA LLAGUNO, MD, PHD**

Senior Research Scientist, Cancer Biology & Genetics Program and Brain Tumor Center  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

**JAMES AMATRUDA, MD, PHD**

Interim Chief and Interim Director, Cancer and Blood Disease Institute  
Childrens Hospital Los Angeles  
Los Angeles, CA, USA

**ALVA ANNETT, MSC**

PhD. Student,  
Department of Human Genetics  
McGill University  
Montreal, Quebec, Canada

**BRADLEY BERNSTEIN, MD, PHD**

Chair of Cancer Biology  
Dana-Farber Cancer Institute  
Boston, MA, USA

**CHRISTOPHER BOOTH, PHD**

Research Fellow  
Dana-Farber Cancer Institute  
Boston, MA, USA

**YLENIA CENDON FLOREZ, PHD**

Research Scholar,  
Department of Cancer Biology and Genetics  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

**TAL COHEN, MD**

Clinical Fellow, Department of Pediatrics  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

**GERALD CRABTREE, MD**

David Korn Professor  
Stanford University School of Medicine  
Stanford, CA, USA

**MYRON K. EVANS II, PHD**

Assistant Professor, Ben Towne Center for Childhood Cancer Research  
Seattle Children's Research Institute  
Seattle, WA, USA

**YUAN GAO, PHD**

Postdoctoral Fellow  
Cold Spring Harbor Laboratory  
Cold Spring Harbor, NY, USA

**EMILY B. HEIKAMP, MD, PHD, MSC**

Instructor in Pediatric Oncology and Stem Cell Transplant  
Dana-Farber Cancer Institute  
Boston Children's Hospital Cancer and Blood Disorders Center  
Boston, MA, USA

**ENRICO MOISO, PHD, MSC**

Senior Computational Biologist,  
Computational Oncology  
Department of Epidemiology and Biostatistics  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

**THOMAS R. W. OLIVER, MD**

Paediatric and Perinatal Pathology  
Specialty Registrar  
Department of Histopathology and Cytology  
Addenbrooke's Hospital  
Cambridge, UK

**#MSKDEVONC #MSKKIDS**

**[msk.org/DevelopmentalOncology](https://msk.org/DevelopmentalOncology)**

# Speakers

**KJ PATEL, FRS, FMEDSCI**

Director of the Weatherall Institute for  
Molecular Medicine  
University of Oxford  
Oxford, UK

**SIOBHAN S. PATTWELL, PHD**

Assistant Professor, Ben Towne Center for  
Childhood Cancer Research  
Seattle Children's Research Institute  
Seattle, WA, USA

**STEPHEN ROBERTS, MD**

Professor of Pediatrics  
Robert C. Neerhout Chair of  
Pediatric Oncology  
Oregon Health and Science University  
Portland, OR, USA

**MICHAEL TAYLOR, MD, PHD**

Director of the Pediatric  
Neuro-Oncology Research Program  
Texas Children's Hospital,  
Baylor College of Medicine  
Houston, TX, USA

**JEFFREY TYNER, PHD**

Professor, Cell, Developmental and  
Cancer Biology  
Co-Lead, Translational Oncology Program  
OHSU Knight Cancer Institute  
Portland, OR, USA

**MASAHIRO UNI, MD, PHD**

Senior Research Scientist,  
Molecular Pharmacology Program  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

**ELVIN WAGENBLAST, PHD**

Assistant Professor  
Icahn School of Medicine at Mount Sinai  
New York, NY, USA

**LILING WAN, PHD**

Assistant Professor,  
Department of Cancer Biology  
University of Pennsylvania  
Philadelphia, PA, USA

**NINA WEICHERT-LEAHEY, MD**

Instructor  
Harvard Medical School,  
Dana-Farber Cancer Institute  
Boston, MA, USA

[#MSKDEVONC](#) [#MSKKIDS](#)

[msk.org/DevelopmentalOncology](https://msk.org/DevelopmentalOncology)

---

## REGISTER ONLINE

# [msk.org/DevelopmentalOncology](https://msk.org/DevelopmentalOncology)

---

### REGISTRATION FEES

Physicians (MDs, PhDs, and DOs)	\$225
Other Healthcare Providers	\$40
Employees of Pharma and Medical Devices*	\$350
Students, Trainees, and Registrants in Low-and Lower-Middle-Income Countries**	Complimentary
MSK Employees	Complimentary

\*Employees who are currently employed by a Pharmaceutical and Medical Device may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

\*\*We are pleased to offer complimentary registration for students and trainees, and registrants residing in low and lower-middle income countries as defined by The World Bank. Please visit the symposium website for details.

### CANCELLATION POLICY

If you wish to cancel your participation in this Symposium, you must email [cme@mskcc.org](mailto:cme@mskcc.org) at least seven (7) days prior to the start of the Symposium, and your refund will be subject to a \$25 administrative fee if attending virtually or a \$100 administrative fee if attending in-person. Cancellations or no-shows within seven (7) days of the Symposium are not eligible for a refund. Please note that if it has been more than 120 days since payment was processed, a W9 form must be submitted in order process your refund and your refund will be issued in the form of a check payment. Refunds are not subject to tax. You may substitute another registrant in your place at any time by contacting [cme@mskcc.org](mailto:cme@mskcc.org) with the appropriate information.

MSK CME reserves the right to cancel or postpone any Symposium due to unforeseen circumstances. In the unlikely event we must cancel or postpone this Symposium, you will be notified via email from MSK CME ([cme@mskcc.org](mailto:cme@mskcc.org)). A full refund will be issued for your registration. MSK CME is not responsible for any related costs, charges, or expenses to participants, including fees incurred by airline/travel/lodging agencies.

Please note the fee for 'Other Healthcare Providers' is non-refundable.

The **Tow Foundation** has been a leading benefactor of Memorial Sloan Kettering since 1976, supporting areas including cell therapies, inflammation and cancer, radiotheranostics, skin cancer research, and, especially, pediatric cancer research. The Foundation's visionary and generous 2018 commitment established the **Tow Center for Developmental Oncology**, which seeks to unite scientists across MSK to develop fundamental insights into the molecular mechanisms of cancers in children and young adults and to devise new approaches for definitive therapy and control.

The **Robert Steel Foundation for Pediatric Cancer Research** was established to honor the memory of Robert Steel, who died in 1984 at the age of eighteen after a heroic two-year struggle against rhabdomyosarcoma. Throughout the years, the Foundation supported MSK programs and initiatives devoted to speeding progress against childhood cancers, and its farsighted generosity has made **The Robert Steel Symposium in Developmental Oncology** possible. By bringing together leading scientists to address the latest challenges and opportunities in pediatric cancer research and treatment, **The Robert Steel Symposium in Developmental Oncology** continues to advance the vital work launched by the **Robert Steel Foundation for Pediatric Cancer Research** more than three decades ago.



Memorial Sloan Kettering  
Cancer Center